文献速递肿瘤 PET/CT

根治性前列腺切除术后生化复发患者经68Ga-PSMA PET/CT分层管理后的3年无进展生存:前瞻性多中心试验结果

3-Year Freedom from Progression After 68Ga-PSMA PET/CT-Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial.
PubMed 文献 · J Nucl Med · 2019-11-01

这项前瞻性多中心研究纳入260例根治性前列腺切除术后生化复发男性,评估68Ga-PSMA PET/CT对挽救性放疗后3年无进展生存(FFP)的预测价值。PSMA PET结果对FFP有高度预测性,阴性或前列腺窝局限病变者FFP为81%,窝外病变者为45%(P<0.0001);PSMA PET预测力优于PSA、T分期、手术切缘和Gleason评分等传统因素。

要点

  • PSMA PET阴性或前列腺窝局限病变者挽救性放疗后3年FFP达81%,窝外病变者为45%。
  • PSMA PET对3年FFP的独立预测力优于PSA、T分期、手术切缘状态和Gleason评分(P<0.002)。
  • PSMA PET阴性未治疗者中66%(19/29)在3年内进展,PSA平均上升1.59 ng/mL。

核心结论

  • PSMA PET结果对根治性前列腺切除术后生化复发接受挽救性放疗男性的3年FFP具有高度预测性。
  • PSMA PET阴性或病变仍局限于前列腺窝者FFP较高,尽管接受的放疗范围较小且追加雄激素剥夺治疗比例较低。

研究设计与样本

  • 前瞻性多中心研究,2015至2017年纳入260例根治性前列腺切除术后PSA升高转诊行PSMA PET的男性。
  • PSMA PET后管理记录但非强制,随访中位38个月(四分位距31-43个月)。

主要发现

  • PSMA PET阴性占34.6%(90/260),前列腺窝局限病变占21.5%(56/260),盆腔淋巴结病变占26.2%(68/260),远处病变占17.7%(46/260)。
  • 71.5%(186/260)接受挽救性放疗:38.2%(71/186)仅前列腺窝,49.4%(92/186)前列腺窝加盆腔淋巴结,12.4%(23/186)仅淋巴结或立体定向体部放疗。
  • 接受挽救性放疗者中64.5%(120/186)达到FFP;PSMA PET阴性或前列腺窝局限者FFP为81%(81/100),窝外病变者为45%(39/86)(P<0.0001)。
  • PSMA PET阴性未治疗者中66%(19/29)进展,3年内PSA平均上升1.59 ng/mL。

关键数值与推荐

  • FFP定义为挽救性放疗后PSA较最低值上升不超过0.2 ng/mL且未追加治疗。
  • 中位PSA为0.26 ng/mL(四分位距0.15-0.59 ng/mL)。

临床怎么用

  • PSMA PET可用于根治性前列腺切除术后生化复发患者挽救性放疗前的分层,预测3年FFP。
  • PSMA PET阴性或前列腺窝局限病变者可考虑较小范围放疗且追加雄激素剥夺治疗比例较低。
  • PSMA PET阴性未治疗者仍有较高进展风险,需密切随访PSA。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

68Ga-labeled prostate-specific membrane antigen (PSMA) PET/CT is increasingly used in men with biochemical recurrence (BCR) after radical prostatectomy (RP), but its longer-term prognostic or predictive potential in these men is unknown. The aim of this study was to evaluate the predictive value of PSMA PET for a 3-y freedom from progression (FFP) in men with BCR after RP undergoing salvage radiotherapy (sRT). Methods: This prospective multicenter study enrolled 260 men between 2015 and 2017. Eligible patients were referred for PSMA PET with a rising level of prostate-specific antigen (PSA) after RP. Management after PSMA PET was recorded but not mandated. PSMA PET protocols were standardized across sites and reported prospectively. Clinical, pathologic, and surgical information; sRT; timing and duration of androgen deprivation; 3-y PSA results; and clinical events were documented. FFP was defined as a PSA rise of no more than 0.2 ng/mL above nadir after sRT, with no additional treatment. Results: The median PSA was 0.26 ng/mL (interquartile range, 0.15-0.59 ng/mL), and follow-up was 38 mo (interquartile range, 31-43 mo). PSMA PET had negative results in 34.6% (90/260), showed disease confined to the prostatic fossa in 21.5% (56/260), showed disease in the pelvic nodes in 26.2% (68/260), and showed distant disease in 17.7% (46/260). Of the patients, 71.5% (186/260) received sRT: 38.2% (71/186) to the fossa only, 49.4% (92/186) to the fossa plus the pelvic nodes, and 12.4% (23/186) to the nodes alone or stereotactic body radiation therapy. PSMA PET was highly predictive of FFP at 3 y after sRT. Overall, FFP was achieved in 64.5% (120/186) of those who received sRT, 81% (81/100) with negative results or fossa-confined findings versus 45% (39/86) with extrafossa disease (P < 0.0001). On logistic regression, PSMA PET was more independently predictive of FFP than established clinical predictors, including PSA, T stage, surgical margin status, or Gleason score (P < 0.002). Thirty-two percent of men with a negative PSMA PET result did not receive treatment. Of these, 66% (19/29) progressed, with a mean rise in PSA of 1.59 ng/mL over the 3 y. Conclusion: PSMA PET results are highly predictive of FFP at 3 y in men undergoing sRT for BCR after RP. In particular, men with negative PSMA PET results or disease identified as still confined to the prostatic fossa demonstrate high FFP, despite receiving less extensive radiotherapy and lower rates of additional androgen deprivation therapy than those with extrafossa disease.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Emmett L, Tang R, Nandurkar R, et al. 3-Year Freedom from Progression After 68Ga-PSMA PET/CT-Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial. J Nucl Med. 2019. PMID: 31676727. doi:10.2967/jnumed.119.235028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。